This Week In HRV - Episode 48

[00:00:00] Welcome back to this Week in Heart Rate Variability. I'm Matt Bennett and as always, this show exists to bring you a clear, honest look at the research shaping how we understand the autonomic nervous system and how that understanding translates into real clinical and practical decisions. Before we get into the science, a quick disclaimer. Nothing in this episode constitutes medical advice. We're discussing peer reviewed research for educational purposes and any clinical decisions should always be made in consultation with a qualified healthcare provider who who knows your specific situation and history. This week we've got seven studies and honestly, it's one of the more wide ranging lineups we've covered in a while, spanning psychiatry, neurology, endocrinology and sports science. We're going to start with a systematic review that tries to make sense of how heart rate variability is actually being used across clinical and research settings right now, because before we can talk about individual findings, it helps to have a map of the terrain we're working within. From there, we'll move into a 10 week study following adolescents with major depressive disorder links, looking at whether autonomic recovery keeps pace with clinical improvement or whether the two can quietly diverge. Then we'll turn to a study on suicide attempts and mood disorders, examining how heart rate variability reactivity interacts with behavioral impulsivity in a way that neither factor explains on its own. After that, something a little lighter in tone, if not in rigor a study on collegiate sprinters and whether the tempo of music played during recovery measurably affects how quickly their heart rate variability bounces back after intense exercise. Following our sponsor break, we'll look at cardiac autonomic modulation and seizure disorders, a study on heart rate variability as a predictor of diabetic polyneuropathy, and finally, a case control study examining the relationship between a hormone called orexin A and heart rate variability in newly diagnosed type 2 diabetes. It's a dense episode, so let's get into it. One thing I'll say before we dive in this week's lineup happens to illustrate almost the entire spectrum of study designs you'll encounter in heart rate variability research, from a broad synthesizing review to prospective cohort studies that follow people forward in time to cross sectional case control comparisons to to a fully randomized controlled experiment. Rather than treating that as incidental, I think it's worth using this episode as something of a working tutorial on how study design shapes the confidence we can place in a finding. So as we move through each study, I'll try to be explicit not just about what was found, but about what kind of evidence it represents. Because that distinction is going to matter for how you weigh each of these findings against the others by the end of the hour. Our first study comes from a team who set out to answer a deceptively simple question. [00:02:16] How exactly is heart rate variability being used in clinical research today? The authors are Camila Maldonado Velas Paola Leon, Claudia Lerma and Juan C. Echeveria, and their work is a systematic review of the recent literature on the application of heart rate variability in clinical practice and research. Here's why this kind of paper matters, even though it doesn't generate a single new physiological data point of its own Heart rate variability has exploded as a research tool over the past several years, and it shows up in cardiology, neurology, psychiatry, sports science, sleep medicine, endocrinology, you name it. But when a field grows that quickly, in that many directions at once, you inevitably start to get fragmentation. Different labs measure different indices. Some report time domain measures like the standard deviation of normal to normal intervals, others focus on frequency domain measures like high frequency power or the ratio of low frequency to high frequency power, and still others lean on non linear methods like point charade, plot analysis or entropy based measures. Without a synthesizing effort that steps back and looks at the whole landscape, it becomes genuinely difficult to know what the field as a collective enterprise, actually agrees on and what remains contested or inconsistently reported. Maldonado, Velles and colleagues screened literature indexed in a major biomedical database, ultimately working with a curated set of 99 articles after applying quality filters designed to exclude studies with insufficient methodological detail or excessive risk of bias. Their goal was to catalog how heart rate variability indices are being applied across three broad clinical cardiovascular disease, neurological conditions, and psychiatric conditions. Within each of these domains, they looked specifically at whether heart rate variability was being used for diagnosis, for staging disease severity, or for tracking disease progression over time, which are three quite different clinical use cases that require different kinds of validation evidence. What they found was a field that is scientifically rich but methodologically inconsistent in ways that matter for anyone trying to translate rather research findings into practice. [00:04:06] Across the 99 studies, there was substantial variability in which heart rate variability indices were reported, how recording durations were standardized, whether recordings were taken supine or seated, and how confounding variables like age, sex, medication status, and comorbid conditions were handled statistically in cardiovascular applications. Reduced heart rate variability was consistently associated with worse outcomes across nearly all the studies reviewed, which is reassuring in terms of the robustness of that general association, but the specific indices used to demonstrate this varied from study to study in ways that make direct apples to apples comparison genuinely difficult. In neurological applications, heart rate variability was frequently used as a marker of autonomic involvement in conditions ranging from stroke to neurodegenerative disease to the seizure disorders we'll discuss later this episode. Again with considerable heterogeneity in method and reporting standards in psychiatric applications, which is an area this show has covered extensively over the life of the podcast. Heart rate variability continues to be explored as a candidate biomarker for conditions like depression and anxiety, though causal directionality, meaning whether reduced heart rate variability contributes to psychiatric symptoms or results from them or both, remains largely unresolved across the body of literature. The authors reviewed the author's central proposal, and I think this is the most practically useful contribution of the paper, is a call for a standardized roadmap for selecting and interpreting heart rate variability indices in future clinical research. They're not proposing new physiological findings here, and they're upfront about that. They're proposing something closer to methodological hygiene. Agree on recording durations across studies within a given clinical domain. Agree on which indices to report by default so that meta analyses become feasible down the line. Agree on how to handle common confounds like age and respiration rate so that the next wave of studies can actually be compared against each other in a meaningful cumulative way, rather than existing as isolated data points. The limitation here is one that's essentially baked into the nature of a systematic review itself, and it's worth being transparent about, rather than treating this kind of paper as though it delivers some kind of definitive verdict. This paper doesn't generate new physiological data, and it's entirely dependent on the quality and completeness of the underlying studies it synthesizes. Publication bias is a real and persistent concern in any review like this. Studies that find significant, exciting associations between heart rate variability and clinical outcomes are simply more likely to get published and more likely to get published in higher profile venues than studies that find null or ambiguous results. Which means the picture painted by any body of published literature is almost certainly skewed toward positive findings in ways that are difficult to fully correct for. The authors are transparent about this constraint, but it's worth naming clearly for our listeners so that the review's conclusions are read with appropriate calibration rather than a settled fact. What this means for practice is mostly a call to humility and precision rather than a specific action item. If you're a clinician or researcher using heart rate variability as a tool, this review is a reminder that the field hasn't yet converged on universal standards. So context matters enormously when comparing your own findings or a patient's own data against the published literature or against normative ranges drawn from other populations. It's less a single finding to apply tomorrow morning and more a lens through which to read everything else we're going to talk about for the rest of this episode. And, honestly, a lens worth carrying into how you read any heart rate variability research going forward. It's also worth pausing on why the authors chose to organize their review around cardiovascular, neurological, and psychiatric applications specifically, rather than, say, organizing by the type of heart rate variability index reported. [00:07:23] That choice reflects how the field itself has actually developed. Historically, heart rate variability research didn't emerge from a single unified theoretical framework. It grew up somewhat independently within cardiology, where reduced variability after a heart attack was recognized decades ago as a marker of elevated mortality risk, within neurology, where autonomic involvement in various conditions has long been of clinical interest, and within psychiatry, where various frameworks propose connections between autonomic state and emotional regulation. Because these three traditions develop somewhat in parallel with limited cross pollination and methodology, a reviewer trying to compare a cardiology paper's frequency domain reporting standards against a psychiatry paper's time domain reporting standards runs into exactly the kind of inconsistency Maldonado VEZ and colleagues are describing. Recognizing that this fragmentation has historical roots rather than being some kind of accident or oversight is useful context for understanding why the field hasn't already self corrected and why a deliberate, coordinated standardization effort rather than organic convergence may be what's actually required going forward. There's a practical skill this review models for anyone who regularly reads heart rate variability literature, whether as a clinician staying current or a researcher designing a new study. And it's worth naming explicitly when you encounter a new heart rate variability paper. One of the first questions worth asking isn't simply what did they find? But which recording protocol, which is specific indices, and which confounding variables did they control for? Because those methodological choices determine how directly comparable a given finding is to everything else you already know from other papers. A finding of reduced high frequency power in one study and a finding of reduced root mean square of successive differences in another aren't automatically telling you the same thing. Even though both indices are often loosely described as reflecting parasympathetic activity, and even small differences in recording duration or body position can meaningfully shift these values, Maldonadoves and colleagues are essentially arguing that the field needs to make this kind of careful methodological comparison easier by converging on shared defaults. But until that convergence happens, the burden falls on individual readers, us included, to do that comparative work ourselves each time we encounter a new study. Our second study takes us into adolescent mental health, and it's one of the more sobering pieces of research we've covered recently on this show. The authors are Heisei Chen, Xiao Najiang, Shah Xuening, Hong Zheng Heyu and Wan Lin Chen, and the paper examines the divergence of clinical and autonomic recovery in adolescent major depressive disorder using a 10 week prospective heart rate variability study with nighttime electrocardiogram monitoring. Major depressive disorder in adolescence is a serious and growing public health concern, and one of the open questions in the field is whether successful treatment, meaning improvement in reported mood and symptom scores as measured by standard clinical instruments, actually corresponds to underlying physiological recovery, or whether the two can proceed on separate tracks. This study set out to test that question directly, using an elegant, if demanding and resource intensive design continuous overnight cardiac monitoring at the start of treatment and again after 10 weeks of routine clinical care. The researchers recruited 50 adolescent inpatients and after careful screening, 43 were confirmed to have unipolar major depressive disorder with a mean age of around 16 and a half years old. These 43 adolescents were followed alongside 43 healthy control participants who are matched as closely as feasible on relevant demographic variables. Both groups underwent three nights of nocturnal electrocardiogram monitoring at baseline, giving the researchers a robust multi night snapshot rather than relying on a single night that might be affected by unfamiliar sleeping conditions or transient stress. And the depressed group was monitored again after 10 weeks of routine treatment with selective serotonin reuptake inhibitor medication, the class of antidepressants most commonly prescribed as first line treatment for adolescent depression. The findings here are genuinely striking and worth sitting with for a moment rather than rushing past. Over the 10 week period, depression and anxiety symptom scores improved significantly in the treated group, which is exactly what you'd hope to see and exactly what most clinical trials of this kind report as their primary endpoint of success. But only about 7% of patients met formal criteria for early clinical response, meaning the rapid, robust improvement clinicians hope for and often expect was actually quite rare, even within a group whose average scores in aggregate were trending in the right direction. That's an important nuance in itself, independent of anything related to heart rate variability. Aggregate improvement across a group can mask the fact that very few individuals within that group are experiencing what we consider a true clinically meaningful early response. Here's where the story gets more concerning and where the autonomic data really earns its place. In this study, the heart rate variability deficits that were present at baseline, meaning the depressed adolescents already showed reduced heart rate variability relative to healthy controls before treatment began, did not normalize over the 10 week treatment period. Instead, the researchers observed a further pathological shift towards sympathetic dominance by the end of the study. The measured through the nocturnal electrocardiogram recordings in plain terms, the balance between the sympathetic nervous system which drives our fight or flight mobilizing responses, and the parasympathetic nervous system which drives rest and recovery. Restorative states move further out of balance over the course of treatment, even as reported mood symptoms were on average improving. There was one clinical measure that tracked with somewhat less sympathetic deterioration reductions in somatic anxiety, meaning the physical symptoms of anxiety like muscle tension, restlessness or physical unease as opposed to purely cognitive or emotional anxiety symptoms. But the authors are careful to frame this correctly and this is a distinction worth being just as careful about ourselves. This association reflects a correlation between less worsening of sympathetic tone and improvement in somatic anxiety symptoms over the study period. It is not evidence that treating somatic anxiety causes true autonomic normalization, nor that reducing somatic anxiety symptoms is a reliable path toward restoring healthy heart rate variability. The finding reveals a dissociation, not a demonstrated mechanism, between partial clinical recovery on one hand and persistent even worsening physiological dysfunction on the other. Let's talk through the limitations here because this study has several that meaningfully shape how we should interpret it. The sample size 43 patients per group is quite reasonable for a study involving intensive multi night overnight monitoring, which is logistically demanding to conduct at scale. But it's not large enough to support strong claims about subgroups or moderating variables within the depressed group. The study is also observational in design rather than a randomized controlled trial comparing different treatment approaches head to head. All patients receive routine selective serotonin reuptake inhibitor treatment and as clinically indicated by their treating physicians, which means the researchers can't isolate the specific contribution of medication itself versus other factors present during an inpatient stay like structured milieu therapy, psychotherapy, sleep regularization or simply the natural passage of time and the episodic course that depression sometimes follows on its own. And because this is a within group perspective design without a treatment versus placebo comparison arm, we should be careful about attributing the observed autonomic pattern purely to medication effects rather than to the broader clinical course of adolescent depression during an inpatient admission. The clinical implication here is significant, though, and I think genuinely important for how we think about treating adolescent depression going forward if confirmed and extended in larger, more diverse samples. This research suggests that we may need to think about depression treatment as having at least two somewhat independent tracks that don't necessarily move the psychological and symptomatic tract, which current first line treatments are reasonably good at addressing within a matter of weeks, and the autonomic and physiological track, which may require different, additional or more targeted interventions entirely, and which current standard care may simply be leaving unaddressed. For clinicians and researchers working with heart rate variability biofeedback tools, this is a meaningful data point suggesting that autonomic dysfunction in adolescent depression might not simply resolve itself as mood symptoms improve on standard treatment and might warrant dedicated direct intervention rather than an assumption that it will follow along passively. There's also a broader developmental consideration worth raising here, one that the authors themselves gesture toward Adolescence is a period of substantial ongoing autonomic nervous system maturation quite apart from any psychiatric illness. Baseline parasympathetic tone, cardiovascular reflex control, and the coupling between respiration and heart rate all continue to develop through the teenage years and early adulthood. That developmental backdrop makes it especially important not to assume the findings from adult depression research simply transfer downward to adolescents unchanged. A sympathetic shift observed in a 16 year old inpatient population may interact with normal developmental trajectories in ways that differ meaningfully from how the same shift would present or resolve in a 50 year old adult with a similar depressive episode. This is part of why a dedicated adolescent specific study like this one carries real value beyond simply extending adult findings to a younger age group. And why the authors call for autonomic specific outcome tracking in adolescent psychiatric care deserves serious consideration rather than being treated as a secondary concern relative to symptom scores alone. I'd also point out how methodologically demanding this study was to actually carry out, because that effort is easy to overlook when we're focused purely on the findings. Recruiting 50 adolescent inpatients successfully completing three full nights of nocturnal electrocardiogram monitoring at two separate time points 10 weeks apart, and doing so alongside a matched healthy control group represents a substantial logistical undertaking, particularly in an inpatient psychiatric setting where clinical priorities and scheduling constraints can make research protocols difficult to execute consistently. The fact that the researchers were able to generate multi night baseline data rather than relying on a single night is a meaningful strength, since single night recordings are more vulnerable to being thrown off by an unfamiliar sleep environment, a particularly restless night, or transient stressors unrelated to the underlying condition being studied. That kind of methodological care is part of why this study's findings, despite the modest sample size, carry real weight within the adolescent psychiatric literature. Our third study stays within psychiatric research but shifts toward one of the most serious outcomes we discuss on this suicide attempts. The authors are Miet, Ersis, Ozankan, Gersha Bazaar, Furkan, Durmusch, and Alpuchuk, and their paper investigates how heart rate variability reactivity moderates the relationship between behavioral disinhibition and suicide attempts and mood disorders. This is a careful, hypothesis driven study asking a fairly precise and clinically motivated question. We know from the broader literature that impulsivity is associated with elevated suicide risk, and we know that autonomic flexibility, meaning the nervous system's capacity to shift appropriately between states in response to acute stress or demand, is often disrupted in people with mood disorders. What this research team wanted to know is whether these two factors interact in a meaningful way, whether impulsivity is especially dangerous, specifically when it's paired with impaired autonomic stress response, rather than either factor simply mattering on its own independently of the other. The researchers studied 61 inpatients experiencing a major depressive episode at the time of assessment. Of these, 23 had a recent history of a suicide attempt and 38 had suicidal ideation without a recent attempt, giving the researchers two clinically distinct comparison groups within the same broader diagnostic population. Each participant had their heart rate variability recorded both at rest, establishing an individual baseline, and during a go no go task, which is a standard behavioral measure of impulse control that asks participants to respond quickly to certain stimuli while withholding responses to others, generating a measure of commission errors, meaning mistaken responses when the participants should have held back and didn't. Here's an important and honest part of this study story, and one that reflects well on the rigor of the research team. When the researchers first looked at simple group comparisons, they found apparent differences between the suicide attempt group and the ideation only group in both resting heart rate variability and go no go task performance differences that on first glance might have seemed like a clean, straightforward story. But once they statistically controlled for age, those apparent group differences disappeared entirely. This is a great example of why controlling for confounding variables matters so much in this kind of clinical research, since age can independently affect both autonomic function and impulse control performance, and the authors deserve real credit for reporting this null result transparently rather than emphasizing only the initial uncorrected comparisons. The finding that did hold up under this more rigorous analysis and the genuine contribution of this paper was an interaction effect. Participants who made more impulsive commission errors on the Go no go task had a history of suicide attempts, specifically when their heart rate variability reactivity to the task, meaning how much their heart rate variability changed from resting baseline during the demanding cognitive task, was blunted rather than robust. [00:18:33] In other words, it wasn't impulsivity alone and it wasn't blended autonomic reactivity alone that characterized the suicide attempt group relative to the ideation only group. It was specifically the combination high behavioral impulsivity paired with an autonomic nervous system that couldn't mount an appropriate flexible stress response under cognitive demand. [00:18:50] The authors themselves describe these findings as exploratory and proof of concept, and that framing is important for us to preserve carefully here rather than overstating the certainty of the result. [00:19:00] This was a cross sectional study, meaning it captured a single snapshot in time rather than tracking people prospectively forward to see who would go on to attempt suicide. So we cannot say that blunted heart rate variability reactivity causes the dangerous combination with impulsivity, only that the two co occur in this particular sample of attempters at this particular point in time. The sample size of 61 participants overall and specifically 23 attemptors within that group is small enough that this interaction effect genuinely needs replication in larger independent samples, ideally with prospective follow up before it should be allowed to influence clinical risk assessment protocols in any formal way. That said, the conceptual model here is compelling and worth taking seriously as a direction for future research. Even in its current preliminary state. It suggests that neither a purely psychological framework focused narrowly on impulsivity and behavior, nor a purely physiological framework focused narrowly on autonomic markers in isolation fully captures suicide risk on its own. The combination motor disinhibition paired with impaired stress related autonomic flexibility may better characterize a specific high risk phenotype worth studying further for clinicians. This points toward a potential future where behavioral impulse control measures and objective physiological reactivity measures are considered jointly as complementary pieces of a risk picture rather than in isolation from one another. Though we are clearly not there yet, given how preliminary this specific finding remains and how much replication work lies ahead, it's worth reflecting for a moment on why an interaction effect like this one is so much harder to detect and so much easier to miss entirely than a simple main effect comparing two groups. Detecting an interaction statistically generally requires a larger sample than detecting either of the two contributing main effects on its own. Because you're essentially asking the data to support a more specific and more conditional claim, not just that impulsivity matters and not just that autonomic reactivity matters, but that the two combine in a particular way only under certain conditions. With 61 total participants, this study is almost certainly underpowered by conventional standards to detect an interaction effect with high confidence, which is precisely why the authors are appropriately restrained in calling this exploratory rather than confirmatory. That restraint is a mark of good scientific practice, not a weakness of the paper. It also means that if a future, larger study fails to replicate this specific interaction, that wouldn't necessarily be a failure of the underlying concept so much as a reminder of how demanding interaction effects are to establish reliably in clinical populations that are by their nature difficult to recruit in very large numbers. It's also worth thinking about what a validated version of this finding might eventually look like in clinical practice, even though we're not there yet. Most current suicide risk assessment tools rely heavily on self report, clinical interview, and history, all of which are valuable, but all of which depend on a patient's willingness and ability to disclose their internal state accurately, something that can be especially difficult to obtain from someone in acute crisis. An objective physiological measure that could be layered onto existing risk assessment, even as a modest supplementary signal rather than a replacement, would represent a meaningfully different kind of information source, one less dependent on disclosure. That's part of what makes this line of research worth continuing to track even at this early stage, though it's equally important to resist the temptation to treat a single blunted heart rate variability reactivity measurement as diagnostic of anything on its own, particularly given how preliminary and unreplicated this specific interaction remains. After two fairly heavy studies. The let's shift into something a bit different in subject matter, though no less rigorous in method. Our fourth study looks at athletic recovery, specifically the effect of music tempo on post exercise heart rate variability in male collegiate sprinters. The authors are Chen Bao, Jiayi Li Ryan Gao, Shiqiang Jiang, and Jeming Wang. Anyone who's spent time around athletic training environments knows that music is nearly ubiquitous, whether it's blasting through a weight room or playing quietly during a cool down. But the actual physiological effects of specific musical properties like tempo on recovery remain surprisingly underexplored in a rigorous, well controlled way. Most of what we hear about music and exercise tends to be either anecdotal or focused narrowly on subjective motivation and perceived exertion during exercise itself, rather than the recovery period that follows. This study set out to change that using a genuinely well powered, systematically randomized design focused specifically on the recovery window. The researchers recruited 265 male collegiate sprinters, a solid sample size for this kind of physiological research, and and randomized them into one of 10 groups, a no music control group or one of nine different music tempo conditions ranging from 50 beats per minute up to 130 beats per minute in 10 beat per minute increments, giving a fine grained gradient across a wide tempo range. Each participant completed a high intensity cycling test designed to elevate heart rate and induce measurable autonomic stress in a standardized, repeatable way and then underwent a recovery period during which their assigned music condition or silence for the control group was played consistently. Heart rate and heart rate variability recovery were tracked throughout this recovery window, allowing the researchers to compare recovery trajectories across all 10 conditions. The finding that stood out was that the 120 beats per minute condition showed comparatively favorable heart rate and heart rate variability recovery relative to the other tempo conditions in the silent control group. For context, 120 beats per minute sits in a moderate tempo range, noticeably faster than a typical resting heart rate, but well short of the kind of high intensity driving tempo you'd associate with peak training playlists designed to pump athletes up during a workout itself. The authors are appropriately cautious in how they frame this finding, and it's a caution worth repeating clearly for our listeners. Rather than letting a single favorable number get oversimplified into a universal rule, they explicitly note that this tempo is not universally optimal, meaning we shouldn't walk away from this study assuming 120 beats per minute is some kind of magic number that applies to everyone in every recovery context, every sport, or or every individual physiology. The relationship between music and autonomic recovery is likely influenced by individual preference, cultural and personal familiarity with certain tempos, the specific type and intensity of exercise being recovered from, and plenty of other factors. This single study, however well designed, wasn't built to isolate or test. The authors call explicitly for further research into music's broader role in mitigating exercise related cardiac risk more generally, which tells you they see this as an opening generative finding rather than a settled final one. [00:24:53] In terms of limitations, it's worth noting clearly that this study was conducted exclusively in male collegiate sprinters, a fairly narrow population in terms of age, sex, competitive level, and training background. Whether these findings generalize to female athletes, older recreational athletes, endurance sport athletes rather than sprinters or non athletes entirely is genuinely unknown from this data alone and shouldn't be assumed without direct testing in those populations. The study also used a single type of exercise stressor, a high intensity cycling test, so the recovery context here is specific to that modality rather than necessarily representative of recovery from, say, resistance training, distance running or team sport competition. For coaches and practitioners working with athletes, the practical takeaway is modest but real and easy to act on. There is now controlled experimental evidence, drawn from a reasonably large sample that moderate tempo music in the neighborhood of 120 beats per minute may support more favorable heart rate variability recovery after intense exercise compared to either faster tempos or silence. It's a low cost, easily implemented variable worth testing individually with athletes in a given training context, while keeping firmly in mind that the underlying research doesn't support treating it as a universal one size fits all prescription for every athlete or every sport. There's an interesting physiological question lurking underneath this finding that the study itself doesn't fully resolve, which is why moderate tempo specifically, rather than slower or faster tempos, would produce more favorable recovery. One plausible mechanism involves what's sometimes called entrainment, the tendency for physiological rhythms, including heart rate, to synchronize somewhat with external rhythmic stimuli. A tempo too far below or above an individual's natural recovery heart rate trajectory might create a kind of rhythmic mismatch, whereas a tempo that sits closer to where heart rate is naturally heading during recovery might support rather than compete with the body's own return toward parasympathetic dominance. [00:26:41] This is speculative and the study wasn't designed to test entrainment directly, but it offers a testable hypothesis for future research, and it's the kind of mechanistic question that would be worth pursuing before this finding gets translated into blanket recommendations across sports science more broadly. That brings us to our sponsor for this episode. This show is proudly sponsored by Optimal hrv, whose mission is to help clinicians, coaches and everyday listeners actually put heart rate variability science into practice rather than leaving it as an academic curiosity. The Optimal HRV app supports a structured morning measurement protocol so you can track your own heart rate variability trends over time under consistent, comparable conditions, along with longitudinal tracking tools that help you see meaningful patterns across weeks and months rather than getting distracted or misled by single day noise, which, as we heard in our very first study today, is a real and persistent challenge across this entire field of research. The app also includes built in biofeedback tools that let you practice the kind of paced breathing and physiological regulation techniques we talk about so often on this show, giving you a direct, hands on way to engage with your own autonomic nervous system rather than just observing it passively. [00:27:47] Optimal HRV also offers professional training for clinicians who want to build heart rate variability biofeedback formally into their practice. There's a comprehensive biofeedback training program taught by Dr. Inakazan, which is approved for 16 continuing education credits through the American Psychological association, covering both the underlying science and the practical clinical skills needed to bring biofeedback into everyday patient care. And for clinicians who want to make sure their practice is grounded in strong ethical and professional standards as they build out this kind of work, there's a second training on Ethical Principles in Practice Standards and Clinical Biofeedback, taught by Dr. Donald Moss, aligned with the standards of the Biofeedback Certification International alliance, and approved for three continuing education credits through the American Psychological Association. For full details and links to both trainings are in the show Notes for this episode, so be sure to check those out if either of these paths interests you. Our fifth study takes us into neurology examining cardiac autonomic modulation and seizure disorders. The authors are Reihan Menon, md, Zabihola Kamlesh, Jha Saran? Ak and Zakiyah Tasnim, and the paper looks specifically at seizure disorders with and without anorectal epileptiform discharges using a retrospective heart rate variability analysis drawn from archived digital electroencephalogram recordings. Interictal epileptiform discharges refer to abnormal electrical brain activity that shows up on an electroencephalogram between seizure events rather than during an active seizure itself. There's long been interest in understanding how seizure disorders affect the autonomic nervous system more broadly, given the well documented risks of cardiac and autonomic complications, including sudden, unexpected death in people living with epilepsy. But this study asked a more specific and narrower question than simply confirming that seizure disorders affect autonomic function Overall, does the mere presence of these interactive discharges, independent of a seizure disorder diagnosis itself, further disrupt autonomic regulation beyond what the underlying condition already produces? The researchers took a resourceful and efficient approach to this question, extracting electrocardiogram signals retrospectively from archived digital electroencephalogram recordings, which allowed them to drive heart rate variability data without needing to run entirely new dedicated cardiac monitoring sessions, since the electrocardiogram channel is often recorded alongside the electroence encephalogram as a matter of routine clinical practice. They studied 45 adults total, divided into three groups of 15 each patients with a seizure disorder who showed interictal epileptiform discharges on their recordings patients with a seizure disorder who did not show these discharges despite otherwise similar clinical presentation and a comparison group of non seizure neurological patients drawn from the same clinical setting. The findings showed that both seizure disorder groups, regardless of whether interictal epileptiform discharges were present on their recordings, had lower vagally mediated heart rate variability than the non seizure neurological control group. Vagally mediated heart rate variability refers to the component of heart rate variability driven primarily by the vagus nerve, the major channel through which the parasympathetic nervous system communicates with and regulates the heart, so lower vagally mediated heart rate variability generally reflects reduced parasympathetic influence on cardiac rhythm and by extension, a shift toward relatively greater sympathetic dominance. However, and this is the specific and more surprising part of the first finding, the presence of interictal epileptiform discharges itself did not further alter resting autonomic measures beyond what was already seen with a seizure disorder diagnosis alone, meaning the two seizure disorder subgroups looked similar to each other on these autonomic measures despite their electrographic differences. [00:30:57] This is a genuinely useful negative finding, and I want to underscore why that's the case. Rather than treating a null result as simply uninteresting, it tells us that autonomic disruption in seizure disorders appears to be a broader feature of the underlying condition and itself, rather than something driven specifically by these interictal electrical abnormalities that show up between seizure events. That's clinically meaningful because it suggests that monitoring for interictal epileptiform discharges as a marker of cardiac autonomic risk, at least based on resting heart rate variability measures, wouldn't add meaningful additional information beyond simply knowing that a patient has a seizure disorder in the first place. Limitations here are considerable and worth naming plainly rather than glossing over. This is a retrospective cross sectional study with a genuinely small sample, 15 patients per group, and the underlying data was repurposed from electroencephalogram recordings collected for other clinical purposes rather than data collected with heart rate variability. As the primary research aim from the outset, we should treat the association between seizure disorders and reduced vaguely mediated heart rate variability as exactly that an association observed in this particular sample, not evidence of a specific causal pathway running in one direction or the other. The retrospective design also means the researchers couldn't control recording conditions as tightly as a prospective, purpose built study would allow, and unmeasured differences between the groups such as anti seizure medication regimens, seizure frequency or time since last seizure could plausibly be influencing the pattern observed here in ways the study wasn't positioned to fully account for even with those caveats firmly in mind. This adds a useful data point to a growing body of literature documenting autonomic vulnerability in people with seizure disorders and reinforces that cardiac autonomic monitoring may be a relevant consideration in this population's broader clinical picture, independent of the specific electrographic features being tracked on any given day or during any given recording session. This study also illustrates a broader methodological trend worth flagging, one that connects nicely back to our opening systematic review the practice of repurposing data collected for one clinical purpose, in this case electroencephalogram monitoring for seizure diagnosis, to answer an entirely different research question about autonomic function. This kind of secondary use research is efficient and can generate genuinely valuable hypotheses without the cost and burden of new data collection, but it also inherits certain constraints from the original recording context. Electrocardiogram signals extracted incidentally from an electroencephalogram setup, for instance, may not always meet the same technical quality standards as a dedicated cardiac recording, and researchers using this kind of approach need to be especially careful about validating signal quality before drawing conclusions. The authors here appear to have done that validation work, but it's a reminder that where data comes from and what it was originally collected for shapes what kinds of claims the data can responsibly support. It's worth situating this finding within the broader clinical concern that motivates most autonomic research in epilepsy in the first place, which is the risk of sudden, unexpected death in epilepsy, a devastating and not fully understood complication believed to involve some combination of seizure related response, respiratory suppression, cardiac arrhythmia, and autonomic dysregulation. Research establishing that autonomic disruption is a general feature of seizure disorders rather than something narrowly tied to a specific electrographic marker like enterictal epileptiform discharges, feeds into that larger effort to understand which patients with epilepsy face the highest cardiac risk and why. This particular study doesn't resolve that larger question, and it wasn't designed to, but it does help narrow the search by ruling out one candidate explanation, namely that interictal discharges themselves are a meaningful independent driver of autonomic risk beyond the underlying diagnosis. That kind of incremental narrowing, even through a modestly sized retrospective study, is how this broader and more consequential research question ultimately gets answered. Our sixth study moves into endocrinology, and it's one of the more clinically actionable pieces of research. In this episode, the authors are Dimitrios Tsilingiris Daniel Schmaltzred, Omar Elde, Suki, Florian Kalb, Victoria Fleca, Ekaterina von Rauchaupt, Teresa Hofer, Stefan Kopf, Thomas Fleming, Stefan Herzig, Anna Honeck, Julia Sundredi, and Zoltan Kender. Their paper asks whether reduced heart rate variability can predict incident diabetic polyneuropathy, meaning nerve damage that develops over time in people living with diabetes before that damage is otherwise clinically apparent. Diabetic polyneuropathy is one of the most common and burdensome complications of diabetes, contributing to chronic pain, loss of protective sensation, an increased risk of foot ulcers and, in advanced cases, amputation. Identifying people at elevated risk before polyneuropathy fully develops has enormous clinical value because earlier identification opens the door to more aggressive glycemic management, closer foot care surveillance and other preventive interventions. While there's still time to act, the study explores whether heart rate variability, already reasonably well established in the literature as a marker of what's called cardiovascular autonomic neuropathy, could also serve as an early warning sign for the separate but physiologically related complication of distal symmetrical polyneuropathy, which refers specifically to nerve damage affecting the hands and feet in a symmetrical glove and stocking pattern. The study included 288 people with diabetes with a mean age of 58, a solid and clinically representative sample for this kind of longitudinal complication. Research at baseline, the researchers found that cardiovascular autonomic neuropathy and reduced heart rate variability were cross sectionally associated with existing distal symmetrical polyneuropathy, meaning people who already had polyneuropathy at the start of the study also tended to show more autonomic dysfunction at that same point in time. As always on this show, we want to flag clearly that this cross sectional piece of the finding reflects an association observed at a single moment in time, not a claim about which condition came first or what caused what in a given individual. The more compelling and clinically important part of this study, though, is the perspective piece that follows. Among 194 participants who did not have distal symmetrical polyneuropathy of baseline, the researchers followed them forward for approximately three years. Baseline cardiovascular autonomic neuropathy independently predicted who would go on to develop incident distal symmetrical polyneuropathy over that follow up window. And this predictive relationship held up consistently across three different diagnostic definitions of polyneuropathy that the researchers tested against their data, which adds meaningful robustness and reduces the concern that the finding is simply an artifact of how polyneuropathy happened to be defined. This perspective design. Following people forward in time from a starting point without the condition to see who subsequently develops it is a genuinely stronger form of evidence than a cross sectional snapshot because it establishes clear temporal order. The autonomic dysfunction was measurably present before the nerve damage emerged as a clinical finding. The authors frame this as positioning heart rate variability as a practical, low cost tool for identifying patients at elevated neuropathy risk, and I think that framing is genuinely earned by the strength of the data here that we should still hold some appropriate variability caveats in mind. Three years, while a meaningful and clinically useful follow up window is still a limited horizon for a chronic, slowly progressing complication like diabetic polyneuropathy, and longer follow up could reveal a somewhat different picture for some patients whose disease progresses more slowly. The study also can't tell us whether intervening on heart rate variability directly, say through biofeedback or other autonomic targeted interventions would actually reduce a given patient's risk of developing polyneuropathy. Only that heart rate variability serves as a useful predictive marker identifying who is already on that trajectory, which is a valid, valuable but distinct kind of clinical information from a proven preventive intervention for clinicians working with diabetic patients. This is one of the more directly practical and immediately applicable findings in the episode. Cardiovascular autonomic neuropathy testing and simple heart rate variability measurement tools that are already reasonably accessible and low cost in many clinical settings appear to carry real predictive value for a separate and consequential diabetic complication, which supports incorporating this kind of monitoring into routine diabetes care as a standard practice rather than treating it as a niche or purely research oriented measure reserved for specialty settings. It's worth briefly explaining why cardiovascular autonomic neuropathy and distal symmetrical polyneuropathy, despite affecting different nerve pathways, might be so closely linked predictively in the first place. Both conditions are thought to arise, at least in part from the same underlying chronic metabolic insult, sustained hyperglycemia, damaging small nerve fibers over time, whether those fibers happen to serve the heart's autonomic regulation or the sensory nerves of the feet and hands. Under this shared mechanism view, cardiovascular autonomic neuropathy isn't just a coincidental bystander that happens to predict polyneuropathy risk. It may be an earlier appearing, more easily measured signal of the same diffused small fiber nerve damage process that will, given enough time, also manifest as polyneuropathy elsewhere in the body. That framing helps explain why the predictive relationship held up so consistently across three different diagnostic definitions of polyneuropathy neuropathy in this study, and it strengthens the case for thinking of heart rate variability testing as a window into a patient's broader small fiber nerve health, not merely a narrow cardiac specific measure. From a healthcare systems perspective, this finding also has appeal because of how it fits into existing diabetes care workflows rather than requiring an entirely new infrastructure, many diabetes clinics already perform some form of annual autonomic or neuropathy screening and heart rate variability recording can often be layered onto an existing visit without requiring specialized equipment beyond what many clinics already have access to for basic cardiovascular monitoring. Compare that to some of the more resource intensive risk prediction tools that require specialized imaging or invasive testing and the practical appeal of a low cost, already familiar measurement like heart rate variability becomes clear. The three year perspective window in this study also aligns reasonably well with typical diabetes follow up intervals, meaning a clinician could realistically incorporate a baseline heart rate variability assessment and use it to inform how closely a given patient's feet and peripheral nerve function should be monitored going forward forward without needing to wait for entirely new infrastructure or specialized referral pathways to be built out. Our seventh and final study for this episode returns to diabetes from a different angle, examining serum orexin A levels alongside heart rate variability parameters in newly diagnosed treatment naive type 2 diabetes. This is a case control study and the authors are Ababi T. Ghebrai, Narayan Dutsoni, Puneet Rijwini, Aparnagarg and MDS Hussain. Orexin A, also known as hippocretin, is a neuropeptide involved in regulating wakefulness, appetite and energy balance, and it has increasingly drawn research interest for its potential roles in metabolic regulation more broadly, beyond its more established connections to sleep wake cycles. This study wanted to know two related things. First, whether orxon A levels differ between people newly diagnosed with type 2 diabetes and healthy controls, and second, whether or XNA levels relate in any meaningful way to heart rate variability parameters within the diabetic group. Specifically, given that both systems metabolic regulation on one hand and autonomic cardiac regulation on the other are already known to be disrupted in diabetes, the researchers compared 100 newly diagnosed treatment naive type 2 diabetes patients, meaning people who had not yet started any diabetes medication of any kind against 50 age matched healthy controls, comparing treatment naive patients specifically is a methodologically important design choice here because it removes medication effects as a potential confounding variable entirely, giving a cleaner, less confounded look at the disease state itself rather than a mixture of disease effects in treatment effects that would be harder to disentangle. The findings showed significantly lower serum orexin A levels in the diabetic group compared to healthy controls, alongside markedly impaired heart rate variability across both time domain and frequency domain parameters, meaning both the basic variability measures calculated directly from beat to beat interval timing and the more complex measures derived from frequency based signal analysis were reduced in the diabetic group relative to controls. Both of these findings, taken on their own, add to existing evidence that type 2 diabetes is involves disruption across multiple physiological systems simultaneously, even at the point of first diagnosis, before any treatment whatsoever has begun to shape the clinical picture. Here's the finding that I think matters most for how we should interpret this study overall, and it's a negative one worth taking seriously rather than glossing over in favor of the more headline friendly positive findings within the diabetic group. Specifically, orexin A levels showed no significant linear correlation with any heart rate variability index that the researchers examined. In other words, even though both orexin A and heart rate variability were independently disrupted in people with newly diagnosed diabetes, the degree of disruption in one didn't meaningfully track with the degree of disruption in the other, at least not in a straightforward linear relationship. The author suggests that these two changes may occur independently, perhaps driven by separate downstream consequences of the same underlying metabolic disease process, rather than through a shared or causal pathway connecting the two directly, and I think that's the responsible and appropriately cautious conclusion to draw from this data. This is a good moment to reiterate a caveat we apply throughout this episode and really throughout the show. More broadly, this is a cross sectional case control design comparing groups at a single point in time, so we can't speak to how these two measures might have evolved together or independently over the actual course of someone's progression toward a type 2 diabetes diagnosis. The absence of a linear correlation also doesn't rule out a more complex nonlinear relationship between the two variables, or an indirect relationship mediated by some third factor entirely that this particular study wasn't designed to capture or test for. And as with our earlier diabetes study this episode, the sample here, while reasonably sized for this kind of specialized biomarker research, is drawn from a single clinical population, which limits how confidently we can generalize these specific findings to other populations of newly diagnosed diabetic patients in different healthcare settings or geographic regions. Practically speaking, this study is a useful and well designed contribution to characterizing the physiological signature of new onset type 2 diabetes, showing clearly that both the metabolic regulatory neuropeptide and cardiac autonomic function are disrupted early, essentially at the moment of diagnosis before treatment has had any chance to intervene. But it also serves as a useful caution against assuming that because two systems are each affected by a disease process, they must therefore be causally linked to one another in some simple, direct way. [00:44:05] Sometimes a disease process disrupts multiple systems in parallel independently of one another, without one disruption driving or causing the other, and this study gives us reasonably clean evidence pointing in that particular direction. It's worth noting how this finding sits in interesting tension with our earlier diabetes study, this episode, the one on cardiovascular autonomic neuropathy predicting polyneuropathy. There we saw a shared mechanism argument for why two seemingly distinct nerve related complications might track together over time. Here we see the opposite pattern, two disrupted systems that don't track each other despite both being downstream consequences of the same disease. Taken together, these two studies are a useful reminder that diabetes doesn't produce a single uniform pattern of physiological disruption that spreads predictably from one system to the next. Instead, it appears to produce a somewhat mosaic pattern where some downstream effects are mechanistically linked and predictive of one another, while others emerge in parallel, independently, driven by shared upstream causes rather than by one directly causing the other. Appreciating that distinction matters for how researchers design future studies chasing relationships between diabetes related biomarkers, since assuming shared mechanism by default without testing for it directly is, as this orexin study did, risks overstating how tightly coupled these systems actually are. There's also a broader point worth making about orexin A, specifically given how much attention this neuropeptide has received in sleep medicine research over the past couple of decades, primarily through its connection to narcolepsy, a condition caused by loss of oryxin producing neurons. Bringing orexin A into diabetes and cardiac autonomic research reflects a broader trend in physiology toward recognizing that signaling molecules rarely stay confined to the single system they refer to, first discovered in just as heart rate variability itself began as a fairly narrow cardiology tool before expanding into psychiatry, neurology and sports science. As our opening systematic review reminded us, orexin A appears to be following a similar trajectory outward from its origins in sleep wake regulation into metabolic and cardiovascular research. Studies like this one, even when they produce a null correlation as their headline finding, are valuable precisely because they help map out where these expanding research trajectories do and don't actually connect to one another in measurable ways. So where does that leave us across these seven studies taken together, a few cross cutting themes stand out to me as I think back over the episode the first is a theme we return to again and again on this show. Heart rate variability is remarkably good at revealing that something is physiologically wrong, often earlier or more sensitively than symptoms alone would suggest. But it is much less reliable on its own at telling us why or revealing the precise mechanism connecting it to whatever else is going on. We saw this clearly in the adolescent depression study, where reported mood symptoms improved while autonomic dysfunction quietly and measurably worsened underneath the surface. We saw it again in the Orexin study, where two independently disrupted systems didn't actually track each other in any straightforward way. And we saw it in the seizure study, where a specific electrographic feature that seemed like it should matter clinically turned out not to add meaningfully to the broader autonomic picture once the underlying seizure disorder itself was accounted for. The second thread running through this episode is about timing and study design, and it's a thread our systematic review at the top of the show primed us to notice the studies that gave us the most confident, actionable conclusions this week. The diabetic polyneuropathy prediction study in particular, were the ones with genuine prospective follow up, watching people forward in time from a clearly defined starting point to see what actually developed. The studies relying purely on cross sectional snapshots, however well conducted and however interesting their findings, consistently required us to hold their conclusions more loosely as associations observed at a single point in time, rather than as demonstrated mechanisms or causal pathways. That's not a criticism of any individual research team, since cross sectional designs are often the necessary and appropriate first step before more resource intensive prospective work becomes feasible or justified. But it's a pattern worth naming explicitly because it directly shapes how much clinical weight each finding should carry right now, today, as opposed to how it might be weighted once further replication and longer follow up become available. The third thread is something our opening systematic review set us up to notice from the very start of the episode. The field's diversity in methods and populations is a genuine strength for exploring how broadly heart rate variability applies as a physiological signal from adolescent psychiatry to collegiate athletics to diabetic neuropathy to epilepsy and beyond. But it also means we as listeners, clinicians and researchers need to stay disciplined about not over extrapolating a finding drawn from one narrow population, like male collegiate sprinters or adolescent psychiatric inpatients, to entirely different populations that the original research never actually studied or included. A fourth and final thread worth naming is how often this week's research pointed toward heart rate variability's value as a marker of vulnerability or risk, rather than as a marker that on its own tells us what to do about that vulnerability. The Diabetic Polyneuropathy study is the clearest example, predicting who will develop nerve damage without telling us whether treating the heart rate variability abnormality directly would prevent it. The suicide attempt study points toward a risk phenotype without yet offering a validated intervention target. [00:48:57] Even the seizure study, in telling us what doesn't add predictive value, is fundamentally about refining how we think about risk stratification rather than treatment. This is worth sitting with because it's tempting, especially for an audience that includes clinicians and biofeedback practitioners, to hear a finding like Reduced heart rate variability predicts complication X and assume that improving heart rate variability must therefore reduce the risk of complication X. That inferential leap from a marker of risk to a validated intervention target is exactly the kind of leap this week's research doesn't yet support, and it's one worth flagging explicitly rather than letting it pass unnoticed. That's our show for this week. As always, thank you for spending this time with us. Whether you're a clinician applying this research directly or with patience, a researcher building on these findings in your own work, a coach thinking about how to support your athletes, or simply someone curious about what your own heart rate variability might be telling you about your own physiology. Until next week, keep measuring, keep questioning, and keep learning. This has been this week in heart rate variability.